Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Connexin43 pseudogene in breast cancer cells offers a novel therapeutic target

Andrew Bier, Irene Oviedo-Landaverde, Jing Zhao, Yael Mamane, Mustapha Kandouz and Gerald Batist
Andrew Bier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irene Oviedo-Landaverde
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jing Zhao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yael Mamane
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mustapha Kandouz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerald Batist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-08-0930 Published April 2009
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Sedimentation properties of ΨCx43 RNA. Hs578T and MDA 435 cell lysates were fractionated by sucrose gradient centrifugation and collected while continuously monitoring the absorbance at 254 nm. Analysis of Cx43/ΨCx43 mRNAs was done using semiquantitative RT-PCR followed by NcoI digestion.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    ΨCx43 is preferentially translated and binds with higher affinity to the translational machinery than Cx43. Cx43V5 and ΨCx43Myc cRNAs were in vitro translated in a cell-free system. Translation products were analyzed by electrophoresis on a 12% SDS-PAGE, transferred, and immunoblotted with V5 and Myc antibodies, respectively. Band intensities were quantified using Scion Image and results were plotted in GraphPad Prism 3.0. A, ratios of concentrations of Cx43V5/ΨCx43Myc were varied from 100 to 0. B, cRNAs were added to the translation reaction with increasing amounts of KCl.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Polyribosome profile analysis of Cx43 mRNA following the addition of ΨCx43 mRNA. Cx43 and ΨCx43 mRNAs were extracted and analyzed as mentioned in Materials and Methods. A, polysome profile for Hs578T neo and Hs578T ΨCx43 cells. B, polysome profile for MDA 231 neo and MDA 231 ΨCx43 cells. Band intensities were quantified using Scion Image and results were plotted in GraphPad Prism 3.0. Cx43 mRNA levels in each fraction were expressed as a percentage of total levels summed over all fractions.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Effects on Cx43 RNA and protein expression in response to exogenous Cx43 and ΨCx43 siRNAs. A, RT-PCR products digested with NcoI from MDA 231 neo and ΨCx43 cells. Cx43 RNA decline was quantified using Scion Image and results were plotted in GraphPad Prism 3.0 as the decline in MDA 231 ΨCx43 cells relative to the control (neo cells). B, Cx43 protein levels were determined by Western blot detection of Cx43 as described in Materials and Methods. C, expression of Cx43 and ΨCx43 RNAs was determined by RT-PCR followed by NcoI digestion in MCF7 cells stably expressing Cx43 and ΨCx43 siRNAs. Band intensities were quantified using Scion Image and results were plotted in GraphPad Prism 3.0. Cx43 and ΨCx43 expression levels were analyzed relative to the control cells (MCF7 PSR). D, Cx43 expression was determined by Western blot of protein lysates from MCF7 cells expressing Cx43 and ΨCx43 siRNAs using Cx43 antibody.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    ΨCx43 knockdown sensitizes cells to chemotherapeutics. A, Cx43 expression levels analyzed by Western blot in MDA 231 cells stably expressing ΨCx43 siRNA. Band intensities were quantified using Scion Image and results were plotted in GraphPad Prism 3.0. Cx43 and ΨCx43 expression levels were analyzed relative to the control cells (MDA 231 PSR). B, IC50 values were estimated from dose-response curves obtained after 48 h of exposure to different doxorubicin and paclitaxel concentrations as indicated in Materials and Methods. Points, mean of four independent experiments; bars, SE. ***, P < 0.0001.

Tables

  • Figures
  • Table 1.

    Expression of Cx43 and ΨCx43 in breast cancer cell lines

    Cell linesΨCx43Cx43 RNACx43 protein
    Hs578T−++++++++
    MDA 231++++++++
    MCF7+++−
    MDA 435++++−
PreviousNext
Back to top
Molecular Cancer Therapeutics: 8 (4)
April 2009
Volume 8, Issue 4
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Connexin43 pseudogene in breast cancer cells offers a novel therapeutic target
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Connexin43 pseudogene in breast cancer cells offers a novel therapeutic target
Andrew Bier, Irene Oviedo-Landaverde, Jing Zhao, Yael Mamane, Mustapha Kandouz and Gerald Batist
Mol Cancer Ther April 1 2009 (8) (4) 786-793; DOI: 10.1158/1535-7163.MCT-08-0930

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Connexin43 pseudogene in breast cancer cells offers a novel therapeutic target
Andrew Bier, Irene Oviedo-Landaverde, Jing Zhao, Yael Mamane, Mustapha Kandouz and Gerald Batist
Mol Cancer Ther April 1 2009 (8) (4) 786-793; DOI: 10.1158/1535-7163.MCT-08-0930
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • A Novel TRAIL-Based Technology for Tumor Therapy
  • Trastuzumab Targeting of Metastatic Esophageal Cancer
  • Mcl-1 Determines the Fate of KSP-Inhibited Cells
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement